Free Trial

InflaRx (NASDAQ:IFRX) Trading Up 2.1% - Here's Why

InflaRx logo with Medical background

Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) were up 2.1% on Wednesday . The stock traded as high as $0.90 and last traded at $0.89. Approximately 215,162 shares were traded during trading, a decline of 27% from the average daily volume of 294,997 shares. The stock had previously closed at $0.88.

Analyst Upgrades and Downgrades

Several research firms have weighed in on IFRX. Cantor Fitzgerald assumed coverage on InflaRx in a research note on Tuesday, April 29th. They set an "overweight" rating and a $10.00 price target on the stock. Raymond James Financial downgraded InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 target price on the stock. in a research note on Thursday, May 29th. Guggenheim upped their target price on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, March 26th. HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of InflaRx in a research note on Friday, March 21st. Finally, Oppenheimer lowered their target price on InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a research note on Thursday, May 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $6.60.

Check Out Our Latest Analysis on InflaRx

InflaRx Trading Up 0.4%

The business has a fifty day moving average of $1.14 and a two-hundred day moving average of $1.54. The company has a market cap of $60.35 million, a price-to-earnings ratio of -1.10 and a beta of 1.29.

InflaRx (NASDAQ:IFRX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. On average, research analysts forecast that InflaRx N.V. will post -1.04 EPS for the current fiscal year.

Institutional Trading of InflaRx

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC acquired a new position in InflaRx in the 4th quarter valued at about $28,000. Walleye Capital LLC purchased a new stake in shares of InflaRx during the 4th quarter worth approximately $51,000. Cubist Systematic Strategies LLC purchased a new stake in shares of InflaRx during the 4th quarter worth approximately $55,000. XTX Topco Ltd purchased a new stake in InflaRx in the 1st quarter valued at approximately $38,000. Finally, Geode Capital Management LLC lifted its stake in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock worth $119,000 after purchasing an additional 11,900 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Company Profile

(Get Free Report)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

Featured Stories

Should You Invest $1,000 in InflaRx Right Now?

Before you consider InflaRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.

While InflaRx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines